Updates are available Correction dated 2024-12-17
Click to view Correction: https://doi.org/10.1038/s41598-024-81223-2
-
Authors
Murata, Koichi
Uozumi, Ryuji
Fujii, Takayuki
Onishi, Akira
Murakami, Kosaku
Onizawa, Hideo
Tanaka, Masao
Morinobu, Akio
Matsuda, Shuichi
- License Information
-
More Information
Article History
Received: 26 November 2023
Accepted: 26 June 2024
First Online: 2 July 2024
Change Date: 17 December 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-024-81223-2
Competing interests
: K. Murata received speaking and/or consulting fees from AbbVie GK; Eisai Co., Ltd.; Pfizer Inc.; Chugai Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharma Corp.; Bristol-Myers Squibb; Daiichi Sankyo Co., Ltd.; Janssen Pharmaceutical K.K.; and Asahi Kasei Pharma Corp. R.U. received consulting fees from Eisai Co., Ltd.; Sawai Pharmaceutical Co., Ltd.; and EPS Corporation. T.F. received speaker fees from AbbVie, Asahi Kasei Pharma Corp., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corp., and Eisai Co., Ltd. A.O. received research grants and/or speaker fees from Pfizer Inc.; Bristol-Myers Squibb; Advantest; Asahi Kasei Pharma Corp.; Chugai Pharmaceutical Co., Ltd.; Eli Lilly Japan K. K.; Ono Pharmaceutical Co.; UCB Japan Co., Ltd.; Mitsubishi Tanabe Pharma Corp.; Eisai Co., Ltd.; AbbVie Inc.; Takeda Pharmaceutical Co., Ltd.; and Daiichi Sankyo Co., Ltd. H.O. received research grants and/or speaker fees from AbbVie Inc.; Asahi Kasei Pharma Corp.; Astellas Pharma Inc.; Eisai Co., Ltd.; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corp.; and Daiichi Sankyo Co., Ltd. K. Murakami received speaker and/or consulting fees from Eisai Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Pfizer Inc.; Bristol-Myers Squibb; Mitsubishi Tanabe Pharma Corp.; UCB Japan Co., Ltd.; Daiichi Sankyo Co., Ltd.; and Astellas Pharma Inc. M.T. received research grants and speaker fees from AbbVie GK; Asahi Kasei Pharma Corp.; Astellas Pharma Inc.; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo Co., Ltd.; Eisai Co., Ltd.; Eli Lilly and Company; Pfizer Inc.; UCB Japan Co., Ltd.; Janssen Pharmaceutical K.K.; Kyowa Kirin Co., Ltd.; Mitsubishi Tanabe Pharma Corp.; Taisho Pharma Co., Ltd.; and Teijin Pharma Ltd. A.M. received honorariums from AbbVie GK; Chugai Pharmaceutical Co., Ltd.; Eli Lilly Japan K.K.; Eisai Co., Ltd.; Pfizer Inc.; Bristol-Myers Squibb.; Mitsubishi Tanabe Pharma Corp.; Astellas Pharma Inc.; and Gilead Sciences Japan. In addition, A.M. has received research grants from AbbVie GK; Asahi Kasei Pharma Corp.; Chugai Pharmaceutical Co., Ltd.; Mitsubishi Tanabe Pharma Corp., Ltd.; and Eisai Co., Ltd. for work outside the scope of this study. S.M. received research grants and/or speaker fees from Astellas Pharma Inc.; Daiichi Sankyo Co., Ltd.; Mitsubishi Tanabe Pharma Corp.; Eisai Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Pfizer Inc., and Asahi Kasei Pharma Corp. All other authors have declared no conflicts of interest.
